Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Epidemiology Insights
Dravet Syndrome Market Insight
Dravet Syndrome Market Drivers
Dravet Syndrome Market Barriers
Request for sample pages
Table of contents
1 Key Insights
2 Executive Summary of Dravet Syndrome
3 SWOT Analysis for Dravet Syndrome
4 Dravet Syndrome Market Overview at a Glance
4.1 Market Share (%) Distribution of Dravet Syndrome in 2017
4.2 Market Share (%) Distribution of Dravet Syndrome in 2030
5 Dravet Syndrome: Disease Background and Overview
5.1 Introduction
5.2 Clinical Features of Dravet Syndrome
5.2.1 Epilepsy
5.2.2 Cognition
5.2.3 Movement disorders
5.2.4 Sudden Death
5.3 Genetics of Dravet Syndrome
5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome
5.3.2 Functional aspects of voltage gate sodium channel mutations
5.3.3 Detection of SCN1A mutations
5.3.4 Inheritance mode and pattern
5.3.5 Dravet Syndrome without SCN1A Alterations
5.4 Signs and Symptoms of Dravet Syndrome
5.5 Pathophysiology
5.6 Diagnosis of Dravet Syndrome
5.6.1 Differential diagnosis
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Incidence of Dravet Syndrome in 7MM
7 Country Wise-Epidemiology of Dravet Syndrome
8 United States
8.1 Assumptions and Rationale
8.2 Incident Population of Dravet Syndrome
8.3 Mutations associated with Dravet Syndrome
8.3.1 Incidence of Dravet Syndrome by Mutation Class
8.3.2 Incidence of Dravet Syndrome by Mutation Type
8.4 Seizure associated cases of Dravet Syndrome
8.5 Gender-specific Incidence of Dravet Syndrome
8.6 Age-specific Incidence of Dravet Syndrome
9 EU-5
9.1 Assumptions and Rationale
10 Germany
10.1 Incident Population of Dravet Syndrome
10.2 Mutations associated with Dravet Syndrome
10.2.1 Incidence of Dravet Syndrome by Mutation Class
10.2.2 Incidence of Dravet Syndrome by Mutation Type
10.3 Seizure associated cases of Dravet Syndrome
10.4 Gender-specific Incidence of Dravet Syndrome
10.5 Age-specific Incidence of Dravet Syndrome
11 France
11.1 Incident Population of Dravet Syndrome
11.2 Mutations associated with Dravet Syndrome
11.2.1 Incidence of Dravet Syndrome by Mutation Class
11.2.2 Incidence of Dravet Syndrome by Mutation Type
11.3 Seizure associated cases of Dravet Syndrome
11.4 Gender-specific Incidence of Dravet Syndrome
11.5 Age-specific Incidence of Dravet Syndrome
12 Italy
12.1 Incident Population of Dravet Syndrome
12.2 Mutations associated with Dravet Syndrome
12.2.1 Incidence of Dravet Syndrome by Mutation Class
12.2.2 Incidence of Dravet Syndrome by Mutation Type
12.3 Seizure associated cases of Dravet Syndrome
12.4 Gender-specific Incidence of Dravet Syndrome
12.5 Age-specific Incidence of Dravet Syndrome
13 Spain
13.1 Incident Population of Dravet Syndrome
13.2 Mutations associated with Dravet Syndrome
13.2.1 Incidence of Dravet Syndrome by Mutation Class
13.2.2 Incidence of Dravet Syndrome by Mutation Type.
13.3 Seizure associated cases of Dravet Syndrome
13.4 Gender-specific Incidence of Dravet Syndrome
13.5 Age-specific Incidence of Dravet Syndrome
14 United Kingdom
14.1 Incident Population of Dravet Syndrome
14.2 Mutations associated with Dravet Syndrome
14.2.1 Incidence of Dravet Syndrome by Mutation Class
14.2.2 Incidence of Dravet Syndrome by Mutation Type
14.3 Seizure associated cases of Dravet Syndrome
14.4 Gender-specific Incidence of Dravet Syndrome
14.5 Age-specific Incidence of Dravet Syndrome
15 Japan
15.1 Assumptions and Rationale
15.2 Incident Population of Dravet Syndrome
15.3 Mutations associated with Dravet Syndrome
15.3.1 Incidence of Dravet Syndrome by Mutation Class
15.3.2 Incidence of Dravet Syndrome by Mutation Type
15.4 Seizure associated cases of Dravet Syndrome
15.5 Gender-specific Incidence of Dravet Syndrome
15.6 Age-specific Incidence of Dravet Syndrome
16 Treatment of Dravet Syndrome
16.1 Current Treatment Practices
16.1.1 First-Line Therapies: Valproic Acid and Clobazam
16.1.2 Second-Line Therapies
16.1.3 Third Line of Therapies
16.2 Treatment Algorithm
17 Unmet Needs
18 Organizations contributing toward Dravet Syndrome
19 KOL’s Views: Dravet Syndrome
20 Case Studies
20.1 Anesthetic Management of Dravet Syndrome
20.2 Dravet Syndrome and Parkinsonism
21 Marketed Drugs
21.1 Diacomit: Biocodex
21.1.1 Drug Description
21.1.2 Mechanism of Action
21.1.3 Regulatory Milestones
21.1.4 Advantages and Disadvantages
21.1.5 Safety and Efficacy
21.2 Epidiolex: GW Pharmaceuticals
21.2.1 Drug Description
21.2.2 Mechanism of Action
21.2.3 Regulatory Milestones
21.2.4 Advantages and Disadvantages
21.2.5 Safety and Efficacy
22 Emerging Therapies
22.1 ZX-008: Zogenix
22.1.1 Product Description
22.1.2 Other Development Activities
22.1.3 Clinical Development
22.1.4 Safety and Efficacy
22.1 Soticlestat: Ovid Therapeutics
22.2 Ataluren: PTC Therapeutics
22.2.1 Product Description
22.2.2 Clinical Development
23 Dravet Syndrome: Seven Major Market Analysis
23.1 Key Findings
23.2 Total Market Size of Dravet Syndrome in 7MM
24 Market Outlook by Country
24.1 The United States: Market Outlook
24.2 United States Market Size
24.2.1 Total Market Size of Dravet Syndrome
24.2.2 Dravet Syndrome Market Size by Therapies
24.3 EU-5 Countries: Market Outlook
24.4 Germany Market Size
24.4.1 Total Market Size of Dravet Syndrome
24.4.2 Dravet Syndrome Market Size by Therapies
24.5 France Market Size
24.5.1 Total Market Size of Dravet Syndrome
24.5.2 Dravet Syndrome Market Size by Therapies
24.6 Italy Market Size
24.6.1 Total Market Size of Dravet Syndrome
24.6.2 Dravet Syndrome Market Size by Therapies
24.7 Spain Market Size
24.7.1 Total Market Size of Dravet Syndrome
24.7.2 Dravet Syndrome Market Size by Therapies
24.8 The United Kingdom Market Size
24.8.1 Total Market Size of Dravet Syndrome
24.8.2 Dravet Syndrome Market Size by Therapies
24.9 Japan: Market Outlook
24.10 Japan: Market Size
24.10.1 Total Market Size of Dravet Syndrome
24.10.2 Dravet Syndrome Market Size by Therapies
25 Market Drivers
26 Market Barriers
27 Appendix
28 Report Methodology
28.1 Sources Used
29 DelveInsight Capabilities
30 Disclaimer
31 About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/